Benefits of UK association to Horizon Europe
A position statement from the Royal Society of Chemistry

Summary
Access to European Union (EU) research and development framework programmes for universities and businesses enhances our global competitiveness by supporting UK scientists to forge links and collaborations between countries, sectors and subjects.

The UK is an active participant in Horizon 2020 and our participation in its successor, Horizon Europe, would bring a wide range of benefits to both the UK and Europe. European Union Member States and the European Parliament are currently agreeing the shape of Horizon Europe, which will run from 2021-2027 with a proposed budget of €97.6bn.

We recommend that:
1. Horizon Europe should continue to support excellence and international collaboration to benefit Europe’s science and innovation base and its citizens.
2. When it leaves the EU, the UK should associate fully to Horizon Europe to preserve and enhance these international collaborations and the many reciprocal benefits they bring to both the UK and the European Union.
3. The UK, EU and other international programmes should seek to align to tackle global challenges.

Funding for research and innovation
1. UK research and innovation has received €5.1bn through Horizon 2020 so far, with nearly a third going to the higher education and research sector.\(^1\)\(^2\)

EU funding is particularly important for chemistry research: in 2016/17 UK universities received 24% of their chemistry funding (£55 million) from sources across the EU.\(^3\) Similarly, UK businesses – especially SMEs – benefit from the funding and collaboration opportunities the EU offers: from 2007 to 2013, UK companies received £1bn in EU funding, of which £658m (65%) went to SMEs.\(^4\)

In a survey of nearly 5,800 members of our chemical sciences community, 75% said EU framework programmes benefit UK science and innovation, compared to only 3% who said their impact has been negative.

Survey respondents identified funding for discovery research as one of the most important aspects of public R&D funding, and one of the hardest to replicate within the UK. The UK has received €1.5bn in European Research Council grants through Horizon 2020 so far, more than any other country.\(^1\)

2. Discovery research in the UK benefits significantly from EU funding and is a vital component of a successful research and innovation sector.

Discovery research underpins current and future research and innovation activities. Whilst its impacts can often be long term, they can lead to ground-breaking discoveries that deliver new technologies or open up completely new avenues of research. EU framework programmes primarily support discovery research through instruments such as the European Research Council (ERC) and Marie Skłodowska-Curie Actions as part of Horizon 2020’s Excellent Science Pillar. The UK is the single largest recipient of funding through this pillar in Horizon 2020 so far.

Survey respondents identified access to international collaborative networks, knowledge and expertise as some of the most important factors of public R&D funding. The UK has collaborated with 133 of the 143 countries participating in Horizon 2020.\(^5\)

International Collaboration
3. The collaborations enabled by EU framework programmes are on a completely different scale to what individual countries or bilateral agreements can achieve.

This is vital in the context of tackling global challenges and advancing discovery research, where we can only achieve progress by bringing together the best people, facilities and equipment in the world. For example, the PharmaSea project is developing potential new drugs for Alzheimer’s and epilepsy. It owes its success to being able to access EU-wide collaborative networks and bring together people with specialist skills not available in any one country.\(^5\)
4. **International collaborations are associated with more highly cited publications.**

An analysis of papers published across our portfolio of 44 journals revealed that papers co-authored by researchers based in different countries or regions have a higher number of mean citations than those with authors from a single country or region.\(^6\) Research funded by EU framework programmes also has a higher average impact in terms of mean citations, significantly higher than research papers funded by the UK Government alone.

5. **To support international collaboration, both through EU framework programmes and partnerships with countries throughout the world, the UK needs a migration system that is flexible, cost-effective, easy to use, and above all welcoming to scientists and their families.**

Mobility is an essential driver for scientific collaboration, and Freedom of Movement across the European Economic Area (EEA) has helped make collaboration through EU framework programmes straightforward. Regardless of when and how the UK leaves the EU, to meet the Government’s ambitions for UK science and innovation we need a better migration system for scientists outside the EEA, and to maintain the ease of mobility currently available to EEA scientists. This system must be more streamlined and cost-effective than the current one and must welcome scientists and their families to the UK, whatever the length of their visit and whatever their career stage. To continue to attract the entrepreneurial scientific talent that has contributed to the UK becoming a global leader in science and innovation, the visa system should also consider the needs of individual entrepreneurs and small to medium enterprises as well as larger, multinational organisations.

### Global Challenges

6. **To support the delivery of the national and global challenges we face, UK scientists must have access to international networks of researchers with relevant knowledge and expertise.**

The nature of mission-led research is that it is broad, involves numerous overlapping disciplines and requires cooperation and collaboration. The chemical sciences community is working to develop innovative technologies to address global societal challenges, from water purification membranes and drought-resistant crops, to new antibiotics, batteries and solar cells. The €5.3bn Innovative Medicines Initiative is the world’s largest public-private partnership in the life sciences, supported by Framework Programme 7 and Horizon 2020. The partnership works towards speeding up the discovery and delivery of new medicines to patients across the world.\(^8\)

An independent report by Mariana Mazzucato, commissioned by the European Commission as part of its preparation of Horizon Europe, states that “Importantly, such challenges cannot be solved by any single European country, no matter how large it may be.”\(^9\)

7. **UK, EU and other international research programmes should remain aligned to tackle global challenges.**

The European Commission’s revised mission areas, which come under the “Global Challenges and Industrial Competitiveness” pillar, cover climate change, cancer, healthy oceans and natural waters, carbon neutral and smart cities, and soil health for sustainable food. Some of these mission areas are closely aligned with the United Nation’s Sustainable Development goals.\(^10\) Being involved in research linked to overlapping national, EU and global challenges enables UK scientists to stay up-to-date in or lead on the latest developments worldwide.

### Contact

The Royal Society of Chemistry would be happy to discuss any of the issues raised in our briefing in more detail. Any questions should be directed to Izzie Radford, policy@rsc.org, 01223 432350.
About us
With around 50,000 members in over 100 countries and a knowledge business that spans the globe, the Royal Society of Chemistry is the UK’s professional body for chemical scientists, supporting and representing our members and bringing together chemical scientists from all over the world. Our members include those working in large multinational companies and small to medium enterprises, researchers and students in universities, teachers and regulators.

1 Vinnova, signed grants from eCORDA, September 2018
2 UK participation in horizon 2020, Department for Business, Energy and Industrial Strategy, May 2018
3 HESA Finances record 2016/17, https://hesa.ac.uk
4 CORDIS, https://cordis.europa.eu
5 http://www.rsc.org/globalassets/04-campaigning-outreach/policy/international-collaborations-create-chemistry/rsc_pharmasea_casestudy_2018.pdf, October 2018
6 International collaborations create chemistry, Royal Society of Chemistry, December 2018
7 Science priorities for Brexit – Evidence Report, House of Commons Science and Technology Committee, July 2017
8 https://www.imi.europa.eu/
9 Mission-oriented research & innovation in the European Union, European Commission, February 2018